{"entity":{"id":"barrios-carlos","kind":"person","name":"Carlos Barrios","aka":[],"tldr":"Carlos Barrios is the most visible Latin American voice in global breast cancer trials and a founder of the region's cooperative group LACOG.","summary":"Carlos Barrios is a medical oncologist and Director of the Oncology Research Center at Hospital São Lucas PUCRS, a co-founder of the Latin American Cooperative Oncology Group (LACOG), and a collaborator with Hospital Israelita Albert Einstein and other major São Paulo centres. He has served on the steering committees of numerous global breast cancer trials and is the most visible Latin American voice in that field, having built LACOG to expand trial access across the region. His publications include analyses of trastuzumab emtansine in HER2-positive advanced breast cancer from the KAMILLA safety trial and a qualitative study of barriers to multidisciplinary breast cancer care in five Latin American countries. His interests are breast cancer, Latin American trials and global oncology.","asOf":"2026-09-08","links":[{"label":"LACOG","url":"https://lacog.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barrios%20CH%5BAuthor%5D%20breast%20cancer%20Latin%20America"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["einstein-sao-paulo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist; Director, Oncology Research Center, Hospital São Lucas PUCRS; Latin American Cooperative Oncology Group","specialisms":["Breast cancer","Clinical trials in Latin America","Global oncology"],"profiles":[{"label":"LACOG","url":"https://lacog.org.br"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Barrios%20CH%5BAuthor%5D%20breast%20cancer%20Latin%20America"}],"papers":[{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆","journal":"Annals of Oncology","year":2020,"doi":"10.1016/j.annonc.2020.06.020"},{"title":"Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer","journal":"ESMO Open","year":2022,"doi":"10.1016/j.esmoop.2022.100561"},{"title":"Barriers and facilitators to provide multidisciplinary care for breast cancer patients in five Latin American countries: A descriptive-interpretative qualitative study","journal":"The Lancet Regional Health - Americas","year":2022,"doi":"10.1016/j.lana.2022.100254"},{"title":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DESTINY-Breast06+trastuzumab+deruxtecan+HER2-low+chemotherapy-naive"},{"title":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2305488","doi":"10.1056/NEJMoa2305488"},{"title":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","journal":"Journal of Clinical Oncology","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TROPION-Breast01+datopotamab+deruxtecan+Bardia"}]},"route":"/people/barrios-carlos/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"institution":[{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","route":"/institutions/anvisa/"},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","route":"/institutions/hcpa-porto-alegre/"},{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","route":"/institutions/einstein-sao-paulo/"}],"idea":[{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/"},{"id":"idea-tr1-lmic-sites-in-pivotal-trials","kind":"idea","name":"Pivotal trials include sites in Africa, South Asia and Latin America, sponsor-funded","route":"/ideas/idea-tr1-lmic-sites-in-pivotal-trials/"}],"paper":[{"id":"paper-destiny-breast06-nejm-2024","kind":"paper","name":"DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer","route":"/key-papers/paper-destiny-breast06-nejm-2024/"},{"id":"paper-natalee-nejm-2024","kind":"paper","name":"NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer","route":"/key-papers/paper-natalee-nejm-2024/"},{"id":"paper-tropion-breast01-jco-2024","kind":"paper","name":"TROPION-Breast01: datopotamab deruxtecan versus chemotherapy in pretreated hormone-receptor-positive breast cancer, and why a PFS win did not translate to survival","route":"/key-papers/paper-tropion-breast01-jco-2024/"}]}}